I think of it this way. In theory the first 4 patients were the worst possible choice in terms of an efficacy study because of the duration and severity of the PD. All that was required from that trial was confirmaton of safety. That they showed any improvement was remarkable. That it should be sustained is even more remarkable.
In theory then, we should get an even better response this time around, at least in some patients.
Passing Through the 20's, page-124
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $18.56M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $2.942K | 271.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3488858 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1690169 | 11 |
View Market Depth
| Last trade - 14.17pm 01/07/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |